ConductScience.org, home

Paper40958736

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.

Ozcan AI and 4 others. J Surg Oncol, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers. Papers, record 40958736. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40958736

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.
PubMed
Journal
J Surg Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-10-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ozcan AIAda Ihttps://orcid.org/0000-0001-5023-8242
2López AAArianexys Aquino
3McKenna MKMary K
4Brenner MKMalcolm K
5Thompson AMAlastair M

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Peritoneal NeoplasmsMajor topic
ImmunotherapyMajor topic
Humans

References288

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117067392Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.Mol Cancer2006https://conductscience.org/library/papers/17067392PubMed
230187278Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery.Ann Surg Oncol2018https://conductscience.org/library/papers/30187278PubMed
333081383Antibody-Drug Conjugates for Cancer Therapy.Molecules2020https://conductscience.org/library/papers/33081383PubMed
435327456Assessing the Future of Solid Tumor Immunotherapy.Biomedicines2022https://conductscience.org/library/papers/35327456PubMed
520090516MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain.Appl Immunohistochem Mol Morphol2010https://conductscience.org/library/papers/20090516PubMed
629329202EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.Cancers (Basel)2018https://conductscience.org/library/papers/29329202PubMed
727663893Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.Cancer Discov2016https://conductscience.org/library/papers/27663893PubMed
833614478Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms.Front Oncol2020https://conductscience.org/library/papers/33614478PubMed
938067347Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/38067347PubMed
1034682772Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials.J Clin Med2021https://conductscience.org/library/papers/34682772PubMed
1132698317Monoclonal Antibodies in Cancer Therapy.Antibodies (Basel)2020https://conductscience.org/library/papers/32698317PubMed
1238086815Therapeutic cancer vaccines: advancements, challenges, and prospects.Signal Transduct Target Ther2023https://conductscience.org/library/papers/38086815PubMed
1337386139Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.Br J Cancer2023https://conductscience.org/library/papers/37386139PubMed
1433178203Localized Interleukin-12 for Cancer Immunotherapy.Front Immunol2020https://conductscience.org/library/papers/33178203PubMed
1525762242Surgical stress response after colorectal resection: a comparison of robotic, laparoscopic, and open surgery.Tech Coloproctol2015https://conductscience.org/library/papers/25762242PubMed
1624337648Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.Ann Surg Oncol2014https://conductscience.org/library/papers/24337648PubMed
1736960052Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials.Front Immunol2023https://conductscience.org/library/papers/36960052PubMed
1838261129Reconnaissance for Intraperitoneal Immunotherapy.Ann Surg Oncol2024https://conductscience.org/library/papers/38261129PubMed
1930962163Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.Mol Ther2019https://conductscience.org/library/papers/30962163PubMed
2035326701Mesothelin: An Immunotherapeutic Target beyond Solid Tumors.Cancers (Basel)2022https://conductscience.org/library/papers/35326701PubMed

See all 288 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
40958736Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.J Surg Oncol2025https://conductscience.org/library/papers/40958736

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40958736

GET https://conductscience.org/api/papers/v1/40958736/references?page=2